Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487849 | 1.00 | MET (0.56) | METCD274KLK7WDR5KMT2A | |
| SCHEMBL30454986 | 0.95 | MET (0.61) | METCD274BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL488567 | 0.95 | MET (0.61) | METCD274BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL30453910 | 0.93 | MET (0.64) | METKMT2ABMPR1BBMPR1ATGFBR1 | |
| SCHEMBL488244 | 0.93 | MET (0.64) | METKMT2ABMPR1BBMPR1ATGFBR1 | |
| SCHEMBL487728 | 0.92 | MET (0.49) | METKLK7KMT2A | |
| SCHEMBL30453447 | 0.92 | MET (0.49) | METKLK7KMT2A | |
| SCHEMBL488212 | 0.91 | MET (0.60) | METCD274 | |
| SCHEMBL30454062 | 0.91 | MET (0.60) | METCD274 | |
| SCHEMBL487903 | 0.88 | MET (0.70) | METCD274BMPR1BBMPR1ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |